Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Julie M. Collins & James L. Gulley. (2019) Product review: avelumab, an anti-PD-L1 antibody. Human Vaccines & Immunotherapeutics 15:4, pages 891-908.
Read now
Read now
Articles from other publishers (12)
Tanuja Yadav, Velisha Mehta, Nilam Bhusare, Meena Chintamaneni & Y. C. Mayur. 2023. Drug Repurposing for Emerging Infectious Diseases and Cancer. Drug Repurposing for Emerging Infectious Diseases and Cancer
111
158
.
Josée Golay & Alain E. Andrea. (2020) Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies 9:2, pages 17.
Crossref
Crossref
Xinmiao Lu, Xiao Li, Ye Peng, Tao Wang, Danni Li, Lina Jia & Lan Zhang. (2019) Radiolabeling and biological evaluation of 125I-Necitumumab for EGFR-targeted SPECT imaging. Journal of Radioanalytical and Nuclear Chemistry 323:1, pages 83-89.
Crossref
Crossref
Liza C. Villaruz, Manuel Cobo, Konstantinos Syrigos, Dimitrios Mavroudis, Wei Zhang, Jong Seok Kim & Mark A. Socinski. (2019) A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Lung Cancer 136, pages 52-56.
Crossref
Crossref
Thies Rösner, Steffen Kahle, Francesca Montenegro, Hanke L. Matlung, J.H. Marco Jansen, Mitchell Evers, Frank Beurskens, Jeanette H.W. Leusen, Timo K. van den Berg & Thomas Valerius. (2019) Immune Effector Functions of Human IgG2 Antibodies against EGFR. Molecular Cancer Therapeutics 18:1, pages 75-88.
Crossref
Crossref
Francesco Agustoni, Kenichi Suda, Hui Yu, Shengxiang Ren, Christopher J. Rivard, Kim Ellison, Charles CaldwellJrJr, Leslie Rozeboom, Kristine Brovsky & Fred R. Hirsch. (2019) EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treatment Reviews 72, pages 15-27.
Crossref
Crossref
Mika K. Kaneko, Shinji Yamada, Shunsuke Itai, Yao-Wen Chang, Takuro Nakamura, Miyuki Yanaka & Yukinari Kato. (2018) Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134. Biochemistry and Biophysics Reports 14, pages 54-57.
Crossref
Crossref
Shima Moradi-Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian & Leila Farahmand. (2018) Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. Journal of Pharmacy and Pharmacology 70:7, pages 841-854.
Crossref
Crossref
Shunsuke ItaiShinji YamadaMika K. KanekoYao-Wen ChangHiroyuki HaradaYukinari Kato. (2017) Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 36:6, pages 272-281.
Crossref
Crossref
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri & Mauro Orlando. (2017) Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Research and Treatment 49:4, pages 937-946.
Crossref
Crossref
Shunsuke ItaiMika K. KanekoYuki FujiiShinji YamadaTakuro NakamuraMiyuki YanakaNoriko SaidohSaori HandaYao-Wen ChangHiroyoshi SuzukiHiroyuki HaradaYukinari Kato. (2017) Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 36:5, pages 214-219.
Crossref
Crossref
David C. Smith, John Powderly, James J. Lee, Dale R. Shepard, Johan Wallin, Archana Chaudhary, Grace Yi Chao, Wee Teck Ng, Malcolm I. Mitchell, Gerrit Grau, Raffael Kurek & Patricia LoRusso. (2016) Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 78:2, pages 271-280.
Crossref
Crossref